RxDoctor Payments Data

Frederick Duggan, MD

Pulmonary Disease · Meridian, MSNPI 1003893652

Payments from drug & device makers

$210in general payments, 2019–2025

Across 15 payments — averaging $14.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$69
  • Vapotherm Inc$43
  • AbbVie$34
  • Inari Medical, Inc.$23
  • Sunovion Pharmaceuticals Inc.$19
  • Insmed, Inc.$16
  • plus $8 from 1 others

What the payments were for

  • Food & beverage$19492%
  • Education$168%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$210 in reported general payments places this provider in the 10th percentile of 101 pulmonary disease providers in Mississippi.

See all pulmonary disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$114,247
Medicare patients
499
Services billed
1,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter207$158,521
Pirfenidone16$58,038
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr66$33,142
Theophylline ErTheophylline Anhydrous178$23,544
Breo ElliptaFluticasone/Vilanterol50$21,112
Spiriva HandihalerTiotropium Bromide27$19,246
EliquisApixaban27$14,964
SymbicortBudesonide/Formoterol Fumarate47$13,786
Spiriva RespimatTiotropium Bromide26$12,992
Fluticasone-SalmeterolFluticasone Propion/Salmeterol78$12,582
OzempicSemaglutide12$12,497
Atrovent HfaIpratropium Bromide17$10,918
Combivent RespimatIpratropium/Albuterol Sulfate14$10,240
Albuterol Sulfate HfaAlbuterol Sulfate264$9,852
Incruse ElliptaUmeclidinium Bromide20$6,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$69$226,029369 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 101 pulmonary disease providers in Mississippi.

Other pulmonary disease in Meridian

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →